Search

Your search keyword '"Turletti, A"' showing total 957 results

Search Constraints

Start Over You searched for: Author "Turletti, A" Remove constraint Author: "Turletti, A"
957 results on '"Turletti, A"'

Search Results

301. Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study

302. Memory management optimization for content routers in DONA

303. PcapWT: An Efficient Packet Extraction Tool for Large Volume Network Traces

304. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial

306. Dose‐dense adjuvant chemotherapy in HER2‐positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.

308. Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study

309. nepi-ng

310. Demo

316. 3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

318. SDN for Public Safety Networks

319. NAB-Paclitaxel (NAB-P) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): Focus on Luminal Cancers. Results from GIM13-AMBRA Study

320. Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13 - AMBRA Study

321. Message delivery in heterogeneous networks prone to episodic connectivity

322. Routing for disruption tolerant networks: taxonomy and design

323. First-line therapy with fulvestrant (FUL) in HR+ve, HER2-ve advanced pre-treated breast cancer (ABC) patients (pts): Results from the GIM-13 AMBRA Study

324. Nab-paclitaxel (Nab-P) in patients (pts) with HER2-ve advanced breast cancer (ABC): A focus on the elderly— Preliminary results of the GIM-13 AMBRA study

325. Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): Final results of the VICTOR-6 study

326. NEPI

327. A Taxonomy of IEEE 802.11 Wireless Parameters and Open Source Measurement Tools

328. Routing in Delay-Tolerant Networks Comprising Heterogeneous Node Populations

329. Aggregation With Fragment Retransmission for Very High-Speed WLANs

331. Rules Placement Problem in OpenFlow Networks: a Survey

333. NAB-Paclitaxel (NAB-P) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): Focus on Luminal Cancers. Results from GIM13-AMBRA Study

334. Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study

335. Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

336. Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): focus on luminal cancers. Results from GIM13 - AMBRA study

337. Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer

338. Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study

339. Nab-paclitaxel in clinical practice: data from the MANTEL study

341. Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): From randomized trials to real-life setting: Results from GIM13 - AMBRA study

342. Composite index of risk shows that benefit from adjuvant dose dense chemotherapy is not confined to triple negative breast cancer

343. Adherence to International ESO-ESMO (ABC) guide-lines in HER2-ve metastatic breast cancer (MBC) patients (pts): Preliminary results of the GIM 13 - AMBRA Study

347. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.

348. Nab-paclitaxel in clinical practice: Preliminary data from the mantel study.

Catalog

Books, media, physical & digital resources